Manufacturing

Webinar Date/Time: Tue, May 2, 2023 11:00 AM EDT

Nathan Pettus, president of Process Systems and Solutions at Emerson, discusses how automation is impacting recent sustainability technologies and solutions.

A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience.

In this article, a simple chromatographic model is proposed that is capable of predicting the impact of pH and ionic strength on HIC chromatograms.

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

The innovation of going from stainless-steel bioreactors to fixed-bed bioreactors shows an evolution in upstream optimization.

SMB technology in the downstream can facilitate the shift to continuous bioprocessing.

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.

Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.

The combination of modular facilities and closed processing offers significant advantages in the production of biopharmaceuticals and is becoming a compelling option for manufacturing.

As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.

Webinar Date/Time: Tue, Apr 18, 2023 11:00 AM EDT

Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Webinar Date/Time: Wednesday, March 29th 2023 7am PDT | 10am EST | 4pm CEST

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.

Pharmaceutical companies have shifted their approach to development of vaccines as a result of the COVID-19 pandemic.

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT

Process and plasmid design optimization, disposable equipment, and flexible platform processes all play important roles.

Decreasing vein to vein time saves lives.

There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.

Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The trends shaping the growth of the biologics outsourcing industry demand attention.